Catalent and Mantra have announced a commercial supply agreement for Mantra’s oral gel product platform.

Catalent will provide formulation development, commercial manufacturing and packaging services at its St. Petersburg, Florida facility for Over the Counter (OTC) products within Mantra’s portfolio addressing 3 concerns: occasional sleeplessness, pain relief and menstrual relief.

Dr. Aris Gennadios, Group President, Pharma and Consumer Health, Catalent, said, “At Catalent, our priority is to support innovators with the expertise, scale and speed to bring self-care products to market. This is the first OTC unit-dose gel technology manufactured by Catalent, and we are proud to support the commercialisation of Mantra’s portfolio.”

Mantra’s products are presented in portable, single-serve pouches that deliver a precise, pre-measured dose without water. Designed as an innovative alternative to traditional tablets, capsules and syrups, the format is intended to make everyday self-care simpler and more convenient for consumers.

By pairing Mantra’s single-serve oral gel format with Catalent's development-to-commercial expertise, established quality systems and scalable manufacturing infrastructure, the supply agreement supports Mantra's transition to commercialisation of its self-care portfolio.

Simon More, CEO and Founder, Mantra, said, “Consumers have changed the way they think about nearly every category of health and wellness, but the way we take everyday medicine has remained largely unchanged. We built Mantra to rethink that experience through a modern format, clean formulations and a more convenient approach to everyday relief. Partnering with Catalent gives us the development expertise, manufacturing capabilities and scale to bring that vision to market.”

This partnership reflects Catalent’s continued commitment to supporting self-care innovators by combining development, manufacturing and packaging solutions to help bring differentiated products to consumers.